Triomics has raised $15m to further develop its oncology-specialised generative AI (GenAI) platform OncoLLM.

OncoLLM is designed to help cancer centres process oncology data at scale and integrates with health system electronic health records (EHR) to complete specific clinical and administrative tasks.

Triomics Prism software pre-screens oncology patients with upcoming appointments to match them to relevant clinical trials while its Harmony software curates EHR data to support reporting, cohort analysis and precision oncology.

After developing an OncoLLM with the Medical College of Wisconsin, a Triomics trial found that within minutes, the platform could identify 90% of eligible patients for clinical trials – a process that could potentially take weeks for qualified nurses to determine.

The trial also found that OncoLLM surpassed the performance of other large language models (LLM), including Mixtral, Qwen and GPT-3.5, as well as matched the capabilities of GPT-4.

Triomics co-founder and chief technology officer (CTO) Hrituraj Singh commented: “Our investments in our core areas of focus have been deliberate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We have successfully merged expertise in two complex functional areas: our AI researchers, who are specialised in customising language models to specific domains, and our clinical staff, who have decades of oncology-specific experience.

“As a result, our software can complement the strengths of these advanced models while also proactively addressing potential flaws, all with the intricacies of cancer research and care in mind.”

Bradley Taylor, chief research informatics officer at the Medical College of Wisconsin and director of the Clinical & Translational Sciences Institute (CTSI) Center for Biomedical Informatics commented: “Most of the solutions on the market today claim they use GenAI, but many lack published evidence.

“Triomics is setting themselves apart by taking a truly collaborative approach to co-developing these models.”

Participants in the Series A fundraising round included Silicon Valley-based firms Lightspeed, Nexus Venture Partners, General Catalyst and Y Combinator.

GlobalData estimates that the total AI market was worth $908.7bn in 2023 and forecasts that it will grow at a compound annual growth rate (CAGR) of 35% from 2022 to 2030. The company forecasts that the global specialised AI application market, which includes GenAI, will be worth $477.6bn in 2030.